Nan Fung Group Holdings Ltd Takes $34.81 Billion Position in Maplight Therapeutics, Inc. $MPLT

Nan Fung Group Holdings Ltd bought a new position in shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 971,253 shares of the company’s stock, valued at approximately $34,809,708,000. Maplight Therapeutics accounts for approximately 26.5% of Nan Fung Group Holdings Ltd’s holdings, making the stock its biggest position. Nan Fung Group Holdings Ltd owned approximately 2.28% of Maplight Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in Maplight Therapeutics in the 4th quarter valued at about $53,000. Blue Owl Capital Holdings LP acquired a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $5,745,000. Geode Capital Management LLC acquired a new position in shares of Maplight Therapeutics during the fourth quarter valued at approximately $6,835,000. Seven Grand Managers LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at approximately $1,756,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Maplight Therapeutics in the fourth quarter worth approximately $34,026,000.

Insiders Place Their Bets

In other news, Director Troy Cox acquired 15,620 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average price of $9.52 per share, with a total value of $148,702.40. Following the completion of the acquisition, the director owned 15,620 shares of the company’s stock, valued at $148,702.40. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James Woodruff Lillie sold 22,082 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $12.54, for a total transaction of $276,908.28. Following the sale, the insider owned 202,380 shares of the company’s stock, valued at approximately $2,537,845.20. The trade was a 9.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.80% of the stock is owned by company insiders.

Maplight Therapeutics Price Performance

MPLT stock opened at $11.36 on Tuesday. Maplight Therapeutics, Inc. has a 1 year low of $9.10 and a 1 year high of $40.43. The firm has a market capitalization of $526.88 million and a PE ratio of -0.27. The business has a 50 day simple moving average of $25.24 and a 200-day simple moving average of $24.25.

Maplight Therapeutics (NASDAQ:MPLT) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.40) by $0.08. On average, equities research analysts expect that Maplight Therapeutics, Inc. will post -5.12 EPS for the current year.

Wall Street Analyst Weigh In

MPLT has been the subject of several research reports. UBS Group cut Maplight Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $52.00 to $13.00 in a research report on Monday, August 10th. Lifesci Capital raised shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Thursday, May 14th. Benchmark reaffirmed a “buy” rating on shares of Maplight Therapeutics in a report on Monday, June 22nd. Wolfe Research reiterated an “outperform” rating and issued a $30.00 target price on shares of Maplight Therapeutics in a research report on Monday, July 27th. Finally, Needham & Company LLC raised their price target on shares of Maplight Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Four equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Maplight Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.